First Horizon Advisors, Inc. Celldex Therapeutics, Inc. Transaction History
First Horizon Advisors, Inc.
- $3.55 Billion
- Q4 2024
A detailed history of First Horizon Advisors, Inc. transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 333 shares of CLDX stock, worth $5,924. This represents 0.0% of its overall portfolio holdings.
Number of Shares
333
Previous 333
-0.0%
Holding current value
$5,924
Previous $11,000
27.27%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CLDX
# of Institutions
198Shares Held
60.8MCall Options Held
960KPut Options Held
675K-
Kynam Capital Management, LP Princeton, NJ5.06MShares$90.1 Million8.11% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$83.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.88MShares$69.1 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$66.8 Million1.82% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.56MShares$63.3 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $832M
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...